Home > Insider Trading > Filing (0001144204-18-060579)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc.	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1559569	Mark Pruzanski	C/O Intercept Pharmaceuticals, Inc. 10 Hudson Yards, Floor 37 New York NY 10001	President & Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2018-11-15	22,394	$8.67	589,199	No	4	M	Direct
Common Stock	Disposition	2018-11-15	18,873	$100.38	570,326	No	4	S	Direct
Common Stock	Disposition	2018-11-15	3,521	$101.13	566,805	No	4	S	Direct
Common Stock	Acquisiton	2018-11-16	27,606	$8.67	594,411	No	4	M	Direct
Common Stock	Disposition	2018-11-16	9,830	$100.38	584,581	No	4	S	Direct
Common Stock	Disposition	2018-11-16	7,949	$101.48	576,632	No	4	S	Direct
Common Stock	Disposition	2018-11-16	7,839	$102.61	568,793	No	4	S	Direct
Common Stock	Disposition	2018-11-16	1,988	$103.29	566,805	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2018-11-15	22,394	$0.00	22,394	$8.67
Common Stock	Option to Purchase Common Stock	Disposition	2018-11-16	27,606	$0.00	27,606	$8.67

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
27,645		2020-08-16	No	4	M	Direct
39		2020-08-16	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person for financial and tax planning purposes.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $100.00 to $100.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.285, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.00 to $101.955, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.025 to $103.02, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.025 to $103.57, inclusive.
This option is fully vested and exercisable.